COCP Company Profile and Key Details

Q: Who are the executives of COCP?

Mr. James J. Martin CPA, CPA, M.B.A., MBAInterim Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.Dr. Roger D. Kornberg Ph.D.Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory BoardDr. Sam Lee Ph.D.Co-Founder, Co-Chief Executive Officer & PresMr. James J. Martin C.P.A., CPA, M.B.A., MBACo-Chief Executive Officer, Chief Financial Officer & Corporation Sec.

NASDAQ : COCP

Cocrystal Pharma

$1.23

-0.01-0.81%

At Close 4:00 PM

59.2

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cocrystal Pharma, Inc. (COCP) stock declined over -0.81%, trading at $1.23 on NASDAQ, down from the previous close of $1.24. The stock opened at $1.25, fluctuating between $1.22 and $1.27 in the recent session.

Stock Snapshot

1.24

Prev. Close

16.96M

Market Cap

1.22

Day Low

-1.62

P/E Ratio

-0.76

EPS (TTM)

-1.41

Cash Flow per Share

1.25

Open

13.79M

Number of Shares

1.27

Day High

72.31%

Free Float in %

2.59

Book Value

53.59K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	1.26	1.28	1.22	1.23	53.59K
Sep 09, 2026	1.18	1.29	1.18	1.24	111.35K
Sep 08, 2026	1.15	1.20	1.12	1.18	61.38K
Sep 04, 2026	1.12	1.14	1.10	1.13	42.92K
Sep 03, 2026	1.16	1.16	1.12	1.13	29.25K
Sep 02, 2026	1.15	1.17	1.11	1.16	55.2K
Sep 01, 2026	1.17	1.17	1.10	1.12	34.76K
Aug 31, 2026	1.10	1.16	1.10	1.16	48.31K
Aug 28, 2026	1.18	1.18	1.10	1.10	28.74K
Aug 27, 2026	1.10	1.17	1.10	1.14	44.94K
Aug 26, 2026	1.13	1.17	1.12	1.12	18.79K
Aug 25, 2026	1.11	1.18	1.10	1.13	71.83K
Aug 24, 2026	1.19	1.19	1.10	1.11	46.04K
Aug 21, 2026	1.19	1.21	1.10	1.15	84.25K
Aug 20, 2026	1.16	1.23	1.13	1.17	175.89K
Aug 19, 2026	1.10	1.15	1.07	1.15	56.3K
Aug 18, 2026	1.08	1.11	1.07	1.08	0
Aug 17, 2026	1.14	1.15	1.09	1.09	29.98K
Aug 14, 2026	1.07	1.13	1.07	1.12	38.3K
Aug 13, 2026	1.11	1.15	1.10	1.10	35.96K

Contact Details

Bothell, WA 98011

United States

https://www.cocrystalpharma.com 786 459 1831

About Company

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

Stock Peers

ARGX

-18.27-1.82%

argenx SE$984.04 REGN

-14.39-1.78%

Regeneron Pharmaceuticals, Inc.$793.26 MDGL

-13.54-2.48%

Madrigal Pharmaceuticals, Inc.$533.12 VRTX

-6.56-1.26%

Vertex Pharmaceuticals Incorporated$514.56 UTHR

-2.96-0.58%

United Therapeutics Corporation$503.86 KRYS

-2.54-0.73%

Krystal Biotech, Inc.$345.55 ONC

-9.2-2.62%

BeOne Medicines AG$341.80 PRAX

-6.73-1.95%

Praxis Precision Medicines, Inc.$338.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

1.2+0.42%

Ligand Pharmaceuticals Incorporated$289.25

Company Overview

Cocrystal Pharma, Inc. (NASDAQ:COCP) closed at $1.23 USD, losing -$0.01 (-0.81%) from the previous close of $1.24. The stock is currently mid-range between its 52-week high and low $0.76 and $2.67. With a market capitalization of about $16.96 million, Cocrystal Pharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.48). Key stats such as the average daily volume over the past year has been around 63.28 thousand shares, in line with its 52-week average. Headquartered in Bothell, WA, Cocrystal Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James E. Sapirstein, the company employs approximately 10 people and listed since February 22, 2012. Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 8.9%, SMA50 4.77%, SMA200 -17.7%). The stock’s 14-day RSI is 59.19 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.3% below its high and over 23.43% above its low. Average 10-day trading volume of 55.49 thousand shares is in line with the 3-month average of 61.35 thousand, indicating normal recent market interest.

Valuation Metrics

Cocrystal Pharma, Inc. trades at a P/E ratio of -1.6, slightly below the S&P 500 average, with a price-to-sales ratio of 51.39 and a price-to-book ratio of 16.24 reflecting a rich premium to book value. The P/FCF stands at -2.08, also above market averages. Compared to sector medians, Cocrystal Pharma, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Cocrystal Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.49. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Cocrystal Pharma, Inc. generated EPS of -$0.94 over the past year. Five-year average earnings growth is -2.62%. Wall Street analysts project EPS growth of 17.38% annually over the next five years. The latest quarter delivered EPS of -$0.23. The next quarter is forecast at -$0.17. Next year's EPS is expected at -$10.95. Cocrystal Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 39.39%. The prior quarter beat by 6.67%. Over the last six quarters, Apple has recorded several small beats. These include -15.26% in November 12, 2025.

Shareholding & Insider Activity

Cocrystal Pharma, Inc. has 19.26 million shares outstanding. The public float is 11.85 million shares, elevated short interest at 3.75% of float. This equals 388.00 thousand shares. The short ratio is 13.67 days. Institutional investors hold 7.59% of the float. Insiders own 30.73%. WILCOX GARY holds 16.95 million shares, Lee Sam has 13.09 million shares and Schinazi Raymond F has 7.67 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cocrystal Pharma has not generated any revenue. Returns are negative, with ROA at -57.53% and ROE at -68.16%.
On valuation metrics, Cocrystal Pharma trades at a P/E of -1.60, P/S of 51.39 and P/B of 16.24. The current ratio is 1.24 and quick ratio is 1.24. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 3181.85 days. Debt-to-equity is 1.28, supported by a cash flow-to-debt ratio of -6.07.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cocrystal Pharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was $1.39M (margin 0.00%). Operating income was - $21.16M (margin 0.0%). Net income was- $17.98M (EPS - $1.86).
The company ended the quarter with $26.43M in cash and short-term investments, a total debt of $1.85M, and net debt of - $24.58M. Total assets were $31.26M, with equity of $26.38M. Financials further reflected weakness, with operating cash flow of - $14.67M, free cash flow of - $14.78M, and capital expenditures of - $118.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Cocrystal Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.07%, with price expected at $1.28 by September 24, 2026, within a range of $1.23 to $1.33 3-Month Outlook: Projected fall of -51.22%, reaching $0.60 by December 09, 2026, with a range of $0.48 to $0.66. 1-Year Outlook: Projected gain of 508.94%, with price at $7.49 by September 10, 2027, within a range of $0.00 to $11.51.

Key Takeaways

Cocrystal Pharma, Inc. (NASDAQ:COCP) shares are flat 7.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cocrystal Pharma, Inc. trading at a premium to the broader market with a P/E of -1.6. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.33, suggesting 1065.04% upside. Our AI forecast model points to short-term strength (4.07% over two weeks), a medium-term fall (-51.22% over three months), and a longer-term gain (508.94% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cocrystal Pharma, Inc. (COCP) stock price?

Cocrystal Pharma, Inc. (NASDAQ: COCP) stock price is $1.23 in the last trading session. During the trading session, COCP stock reached the peak price of $1.27 while $1.22 was the lowest point it dropped to. The percentage change in COCP stock occurred in the recent session was -0.81% while the dollar amount for the price change in COCP stock was - $0.01.

COCP's industry and sector of operation?

The NASDAQ listed COCP is part of Biotechnology industry that operates in the broader Healthcare sector. Cocrystal Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of COCP?

Mr. James J. Martin CPA, CPA, M.B.A., MBA
Interim Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.
Dr. Roger D. Kornberg Ph.D.
Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Sam Lee Ph.D.
Co-Founder, Co-Chief Executive Officer & Pres
Mr. James J. Martin C.P.A., CPA, M.B.A., MBA
Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.

How COCP did perform over past 52-week?

COCP's closing price is 61.84% higher than its 52-week low of $0.76 where as its distance from 52-week high of $2.67 is -53.93%.

How many employees does COCP have?

Number of COCP employees currently stands at 10.

Link for COCP official website?

Official Website of COCP is: https://www.cocrystalpharma.com

How do I contact COCP?

COCP could be contacted at phone 786 459 1831 and can also be accessed through its website. COCP operates from 19805 North Creek Parkway, Bothell, WA 98011, United States.

How many shares of COCP are traded daily?

COCP stock volume for the day was 53.59K shares. The average number of COCP shares traded daily for last 3 months was 63.28K.

What is the market cap of COCP currently?

The market value of COCP currently stands at $16.96M with its latest stock price at $1.23 and 13.79M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	10
Beta	1.43
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

COCP Company Profile and Key Details

Cocrystal Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Technical Performance

Valuation Metrics

Key Takeaways

Price Forecast & Outlook